Navigation Links
FDA Advisers Consider New Lupus Drug
Date:11/16/2010

By Steven Reinberg
HealthDay Reporter

TUESDAY, Nov. 16 (HealthDay News) -- U.S. Food and Drug Administration advisers were weighing Tuesday whether to recommend the first new drug in more than 50 years to treat the autoimmune disease lupus.

The drug, belimumab (Benlysta), is a so-called monoclonal antibody drug developed to treat patients who suffer from systemic lupus erythematosus.

In research papers submitted to the advisory committee, the full FDA expressed some concerns about the efficacy and safety of the drug.

"I really do think the drug is efficacious," said Sandra C. Raymond, president & CEO of the Lupus Foundation of America, who was attending the advisory panel meeting. "What I'm hearing in terms of efficacy is pretty strong."

The FDA said it wants the advisory panel to look at both the efficacy data, which according to the agency is modest, and the safety data, which the agency believes raises some serious issues. Specifically, the drug has been linked to depression and suicide.

Raymond noted that many patients with lupus suffer from depression. And many patients in clinical trials testing the drug were also taking antidepressants, she added.

The advisory committee is scheduled to vote on whether the drug's risks are mitigated by the benefits it has to offer to patients who are already receiving standard care.

The agency said it is basing its concerns on the results of two phase 3 trials that compared Benlysta with a placebo.

"The risks associated with belimumab include infection, malignancy, suicidality, and overall number of deaths with a numerical imbalance that favored placebo treatment over belimumab treatment," according to the FDA.

Safety is important, Raymond said, but the drugs used to treat lupus now carry some significant side effects, too. "The safety of some of our medications is not good," she said. "So what are we comparing it to?"

The current treatments include chemotherapy and steroids, which can leave the door open to infections, cancers and other unwanted consequences, Raymond said.

Dr. Joan Merrill, head of Clinical Pharmacology at the Oklahoma Medical Research Foundation and medical director of the Lupus Foundation of America, added that "the safety data on Benlysta looks better than we usually see with biologics."

"We have to keep in mind that there is a natural ceiling on the percentage of patients who can respond to any targeted treatment. We do not yet know exactly how good Benlysta is," Merrill said.

What is known is that Benlysta was shown to be statistically superior to a placebo in two phase 3 trials, she said.

"I hope that the FDA will be able to approve it, after they complete the serious deliberations that they must make on all the data," Merrill said.

Lupus is an autoimmune disease in which the body produces antibodies that attack and destroy healthy tissue. This can damage joints, skin, blood vessels and organs. Benlysta works by inhibiting the production of these antibodies.

Benlysta is made by Human Genome Sciences and GlaxoSmithKline.

While the FDA is not bound by its advisory committees' recommendations it usually does so.

More information

To learn more about lupus, visit the Lupus Foundation of America.

SOURCES: Sandra C. Raymond, President & CEO, Lupus Foundation of America; Joan Merrill, M.D., head, Clinical Pharmacology, Oklahoma Medical Research Foundation, Medical Director, Lupus Foundation of America


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Advisers Back Anemia Drugs for Kidney Patients
2. FDA Advisers Consider Approval of Genetically Modified Salmon
3. FDA Advisers Weigh Approval of Genetically Modified Salmon
4. FDA Advisers Divided on Whether to Ban Diet Drug Meridia
5. FDA Advisers Say Avastin Shouldnt Be Used for Breast Cancer
6. FDA to Broaden Disclosure on Advisers Conflicts of Interest
7. FDA Advisers Urge Stricter Regulation of Tanning Beds
8. Considerable proportion of patients with advanced cancer continue to undergo common cancer screening
9. ConnectedIn Divorce Resource Offers Online Expert Website for People Considering or Going Through Divorce
10. BMEGateway's 20th Anniversary Insurance Symposium considered a “Tremendous” Success
11. Newly Relaunched Autoinsurance.net Offers Consumers Smart Tips To Consider When Purchasing Car Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Advisers Consider New Lupus Drug
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: